To receive the Femtech World newsletter, sign up here.
News
BioInnovation Institute & Science to recognise researchers in women’s health
The BioInnovation Institute (BII) has announced the launch of the BII & Science Translational Medicine Prize for Innovations in Women’s Health and Gender Medicine.
The announcement follows the successful BII & Science Prize for Innovation, which is now in its third year and recognises and celebrates bold researchers asking fundamental questions at the intersection of life sciences and entrepreneurship.
The introduction of the Translational Medicine Prize for Innovations in Women’s Health and Gender Medicine seeks to honour researchers who have developed innovative advances with translational potential to impact women’s health and gender medicine globally.
Contributions within any area of women’s health and gender medicine will be considered, including maternal health and chronic gynaecological diseases, reproductive health including female and male contraception and infertility, or elucidation of sex- and gender-specific approaches to conditions that affect women differently or disproportionately.
The winner will have their essay published in the Journal, Science Translational Medicine, and will receive a cash reward of US$25,000 to further progress their research.
Jens Nielsen, chief executive officer of BII, said: “We are proud to introduce this prize alongside Science Journals, following the success of our innovation prize.
“Women’s Health remains a core focus for BII, and we continue to support early-stage start-ups and projects in the field, through programmes such as our collaboration with Ferring Pharmaceuticals.
“We hope this award, which will be announced in 2025, provides the well-deserved recognition of the researchers leading the way in this underserved area of research.”
Sudip Parikh, chief executive officer and executive publisher of Science Journals, added: “With approximately just one per cent of healthcare research and innovation invested in female-specific conditions beyond oncology, it is a highly underserved area of healthcare.
“That is why we are pleased to be working alongside BII again to launch this award to recognise researchers who are developing innovative solutions to address female specific conditions.”
Women’s Health is a focus area for BII – the institute’s Women’s Health Initiative aims to support women’s health start-ups and projects across a broad range of indication areas.
This new award is hoped to highlight researchers who are striving to address crucial challenges in women’s health using creative approaches.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






